Abstract
T cells have originally occupied central stage of the debate on the type of lymphocytes governing the pathogenesis of Sjögren’s syndrome (SS). However, B cells has since been substituted for T cells, and insights into their functions have revealed that they accomplish various tasks. Beyond the paradigm that T lymphocytes maintain strict control over B lymphocytes, these latter cells solicit their own help from the former, release a flurry of cytokines, and act as antigen- presenting cells. In SS, excessive of the B cell-activating factor (BAFF) may cause B-cell quantitative anomalies, such as inflation of mature B (Bm)2/Bm2’ cells in the circulation, or accumulation of transitional type 2, marginal zone (MZ) and memory B cells within the exocrine gland infiltrates. These excesses are also associated with B-cell qualitative anomalies, such as the internal synthesis of BAFF, and a default mechanism that promotes the autoantibody production in ectopic germinal centers or MZ equivalents. Thus, SS should rather be conceived as a quintessential model for B cellinduced autoimmunity. Such a view opens novel prospects for treatment, and indeed B cell-ablative therapy has already been shown to be beneficial to these patients.
Keywords: B lymphocyte, Sjogren's syndrome, B cell activating factor, ectopic germinal centers, T cells, pathogenesis, lymphocytes, cytokines, antigen-presenting cells, marginal zone, internal synthesis, MZ equivalents, B cell-ablative therapy, salyvary gland (SG), rheumatoid arthritis (RA).
Current Pharmaceutical Biotechnology
Title:B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
Volume: 13 Issue: 10
Author(s): Pierre Youinou, Alain Saraux and Jacques-Olivier Pers
Affiliation:
Keywords: B lymphocyte, Sjogren's syndrome, B cell activating factor, ectopic germinal centers, T cells, pathogenesis, lymphocytes, cytokines, antigen-presenting cells, marginal zone, internal synthesis, MZ equivalents, B cell-ablative therapy, salyvary gland (SG), rheumatoid arthritis (RA).
Abstract: T cells have originally occupied central stage of the debate on the type of lymphocytes governing the pathogenesis of Sjögren’s syndrome (SS). However, B cells has since been substituted for T cells, and insights into their functions have revealed that they accomplish various tasks. Beyond the paradigm that T lymphocytes maintain strict control over B lymphocytes, these latter cells solicit their own help from the former, release a flurry of cytokines, and act as antigen- presenting cells. In SS, excessive of the B cell-activating factor (BAFF) may cause B-cell quantitative anomalies, such as inflation of mature B (Bm)2/Bm2’ cells in the circulation, or accumulation of transitional type 2, marginal zone (MZ) and memory B cells within the exocrine gland infiltrates. These excesses are also associated with B-cell qualitative anomalies, such as the internal synthesis of BAFF, and a default mechanism that promotes the autoantibody production in ectopic germinal centers or MZ equivalents. Thus, SS should rather be conceived as a quintessential model for B cellinduced autoimmunity. Such a view opens novel prospects for treatment, and indeed B cell-ablative therapy has already been shown to be beneficial to these patients.
Export Options
About this article
Cite this article as:
Youinou Pierre, Saraux Alain and Pers Jacques-Olivier, B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273100
DOI https://dx.doi.org/10.2174/138920112802273100 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
25th Anniversary Special Issue.
Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more
Advanced Hybrid Solutions: Smart Bioinspired Materials and Platforms for Tissue Engineering and Regenerative Medicine
Bioinspired materials are redefining the landscape of regenerative medicine by mimicking the form and function of natural tissues. The integration of smart polymers and ceramic-based systems into hybrid platforms enables the design of biomaterials that are not only biocompatible and structurally supportive but also functionally dynamic. These advanced hybrid solutions ...read more
Applications and Challenges of Nano-Biotechnology
This thematic issue aims to introduce readers to the fascinating intersection of nanotechnology and biology. It will bring together fundamental principles, materials, tools, and recent breakthroughs to help learners, researchers, and innovators understand how nanoscale science is revolutionizing biological and medical applications. Contributing authors will submit papers related to foundational ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Otorhinolaryngological Manifestations in Sjogren Syndrome
Current Immunology Reviews (Discontinued) Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Current Topics in Medicinal Chemistry From Molecular Mechanism to the Etiology of Sjogren Syndrome
Current Pharmaceutical Design Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone
Current Rheumatology Reviews Kikuchi-Fujimoto Disease: A Distinct Pathological Entity but also an "Overlap" Autoimmune Syndrome: A Systematic Review
Current Rheumatology Reviews Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Chemokines in Rheumatic Diseases
Current Drug Targets The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases
Current Pharmaceutical Design A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Influence of Hormones on Sjögren’s Syndrome
Current Pharmaceutical Design Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren’s Syndrome
Current Rheumatology Reviews Fangchinoline, an Extract of the <i>Stephania tetrandra</i> S. Moore Root, Promoted Oxidative Stress-induced DNA Damage and Apoptosis and Inhibited Akt Signaling in Jurkat T Cells
Current Molecular Pharmacology History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Substance P in Rheumatic Diseases
Current Rheumatology Reviews